PfizerGan Stirs the Pot, Boston Pharma’s $600M Bang & HepC Drug Pricing Back in the News

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.